Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus CURRETAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus CURRETAB.
AYGESTIN vs CURRETAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Category C
Category C
Progestin
Progestin